Multiple myeloma is basically an incurable cancer. Most patients respond initially to chemotherapy with reduction in bone marrow (BM) plasma cells and monoclonal lg levels, but the disease nearly always recurs and becomes refractory to therapy. The objective of this study was to characterize the expression of the multidrug transport pump, P-glycoprotein 170 (P-gp), in myeloma. The great majority of B cells from peripheral blood mononuclear cells (PBMCs) in myeloma express P-gp, detected by the monoclonal antibody MRK-16. P-gp+ blood B cells exhibit extensive DNA hyperdiploidy, suggesting replicative abnormality characteristic of malignant growth. We speculate these represent a stem cell population in myeloma. The proportion of B cells expressing P-gp was comparable among untreated myeloma patients and those treated with chemotherapy. biologic response modifiers, or off treatment. Among BM cells, P-gp was absent or low in untreated myeloma patients but was expressed at high levels on BM cells from patients previously treated with chemotherapy. For untreated patients the majority of B/plasma cells expressing P-gp are located in PBMCs, not the BM cells. Flow cytometric analysis of rhodamine 123 dye efflux indicated a functional P-gp that was efficiently blocked by verapamil ULTIPLE MYELOMA is a hematologic cancer characterized by accumulations of monoclonal plasma cells in the bone marrow (BM), a high serum or urine concentration of monoclonal immunoglobulin, and lytic lesions of the bone.' Although most patients respond to initial chemotherapeutic treatment, nearly all relapse and become refractory to further treatment. The mean lifespan postdiagnosis is approximately 3 years.24 Neither the decrement in M protein,' nor degree of plasma cell kill5 correlate with survival of myeloma patients. Although most attention has focussed on the plasma cells resident in the BM, recent reports implicate a circulating B-lymphocyte population in the pathogenesis of myeloma. 0006-4971/94/8303-0003$3.00/0 724 or cyclosporin A (CsA). Both the CD1 1 bhi CD1 9+ B cells and the T cells in myeloma PBMCs had active CsA-inhibited dye efflux, but monocytes lacked the ability to efflux dye. Nearly all CD38"' plasma cells from myeloma BM cells retained dye, indicating their lack of a functional transport pump. Thus, PBMC B cells may be the predominant set of drug-resistant tumor cells. Myeloma PBMC B cells were cultured with Adriamycin with or without CsA and drug toxicity evaluated by the induction of apoptosis, using flow cytometry to quantitate DNA disruption. No apoptosis was detectable at 0.01 pg/mL adriamycin, the in vivo steadystate level. with or without CsA. With 0.1 pg adriamycin, no apoptosis was detectable in the absence of CsA, but with CsA, 66% of B cells initiated DNA disruption, whereas most T cells were spared. This work suggests that currently used drug dosages are too low to effect P-gp+ B-cell death, even in the presence of CsA. We suggest that blood B cells comprise a highly drug-resistant subset of the myeloma B lineage that escapes conventional chemotherapy and may underlie the almost uniform fatal relapse in myeloma patients.
By Linda M. Pilarski and Andrew R. Belch Multiple myeloma is basically an incurable cancer. Most patients respond initially to chemotherapy with reduction in bone marrow (BM) plasma cells and monoclonal lg levels, but the disease nearly always recurs and becomes refractory to therapy. The objective of this study was to characterize the expression of the multidrug transport pump, P-glycoprotein 170 (P-gp), in myeloma. The great majority of B cells from peripheral blood mononuclear cells (PBMCs) in myeloma express P-gp, detected by the monoclonal antibody MRK-16. P-gp+ blood B cells exhibit extensive DNA hyperdiploidy, suggesting replicative abnormality characteristic of malignant growth. We speculate these represent a stem cell population in myeloma. The proportion of B cells expressing P-gp was comparable among untreated myeloma patients and those treated with chemotherapy. biologic response modifiers, or off treatment. Among BM cells, P-gp was absent or low in untreated myeloma patients but was expressed at high levels on BM cells from patients previously treated with chemotherapy. For untreated patients the majority of B/plasma cells expressing P-gp are located in PBMCs, not the BM cells. Flow cytometric analysis of rhodamine 123 dye efflux indicated a functional P-gp that was efficiently blocked by verapamil ULTIPLE MYELOMA is a hematologic cancer characterized by accumulations of monoclonal plasma cells in the bone marrow (BM), a high serum or urine concentration of monoclonal immunoglobulin, and lytic lesions of the bone.' Although most patients respond to initial chemotherapeutic treatment, nearly all relapse and become refractory to further treatment. The mean lifespan postdiagnosis is approximately 3 years.24 Neither the decrement in M protein,' nor degree of plasma cell kill5 correlate with survival of myeloma patients. Although most attention has focussed on the plasma cells resident in the BM, recent reports implicate a circulating B-lymphocyte population in the pathogenesis of myeloma. The blood of all myeloma patients often includes a very large component of monoclonal B-lineage cells, predominantly late-stage B cells.637 These B cells are monoclonal as defined by their heavy-chain Ig rearrangements:.' restricted expression of either K or X-light chain mRNA,9 and the presence ofmonoclonal cytoplasmic light chain." These monoclonal B cells have extensive DNA aneuploidy,' presumptive evidence of malignancy. They or cyclosporin A (CsA). Both the CD1 1 bhi CD1 9+ B cells and the T cells in myeloma PBMCs had active CsA-inhibited dye efflux, but monocytes lacked the ability to efflux dye. Nearly all CD38"' plasma cells from myeloma BM cells retained dye, indicating their lack of a functional transport pump. Thus, PBMC B cells may be the predominant set of drug-resistant tumor cells. Myeloma PBMC B cells were cultured with Adriamycin with or without CsA and drug toxicity evaluated by the induction of apoptosis, using flow cytometry to quantitate DNA disruption. No apoptosis was detectable at 0.01 pg/mL adriamycin, the in vivo steadystate level. with or without CsA. With 0.1 pg adriamycin, no apoptosis was detectable in the absence of CsA, but with CsA, 66% of B cells initiated DNA disruption, whereas most T cells were spared. This work suggests that currently used drug dosages are too low to effect P-gp+ B-cell death, even in the presence of CsA. We suggest that blood B cells comprise a highly drug-resistant subset of the myeloma B lineage that escapes conventional chemotherapy and may underlie the almost uniform fatal relapse in myeloma patients.
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appear programmed for traffic and invasion based on their expression of CD 1 1 b,9 a p2 integrin required for extravasation, and 81 integrins required for binding to extracellular matrix.I2 Upon chemotherapeutic treatment, plasma cells in the BM disappear, but circulating B cells persist and in some cases even increase in absolute number in A preliminary report suggested that these blood B cells are multidrug resistant. 13 We speculate that these circulating B cells represent a stem cell compartment of myeloma responsible for populating the BM with end stage plasma Multidrug resistance in many malignancies involves an adenosine triphosphate (ATP)-dependent transport pump, p-glycoprotein (P-gp), encoded by the MDRI gene, which mediates drug P-gp appears to play a role in the development of refractory disease in myeloma, but the expression of a functional P-gp transport pump on the BM plasma cells is controversiaI.'4.1'-24 Cytoplasmic P-gp is sometimes dete~table,'~.'~ but others have not found P-gp on the surface or in the ~y t o p l a s m ,~~. '~ or that the myeloma plasma cells contain mRNA.26,27 Treatment of myeloma patients with chemotherapy in the presence of agents known to block P-gp has met with some success. These include calcium channel blockers such as ~e r a p a m i l , l~. " *~~ and cyclosporin A (CsA)." The latter inhibits drug transport by a mechanism independent of its immunosuppressive activit^.*^ Although for myeloma, the intended target of these treatments is the monoclonal plasma cell, the actual target is unknown. A successful response may be caused by the elimination of malignant B cells outside the BM.
This leads to the hypothesis that expression of MDRIencoded P-gp on blood B cells may be responsible for their persistence in myeloma despite chemotherapy. In this study, the phenotypic expression and functional activity of P-gp on blood B cells from myeloma patients was analyzed. 
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We find consistently high expression and function of P-gp on B cells from nearly all patients tested. The function of the P-gp pump was blocked by verapamil and CsA. In vitro treatment of blood B cells from myeloma patients with Adriamycin plus CsA, but not adriamycin alone, resulted in extensive apoptosis within the B but not the T-cell compartment.
MATERIALS AND METHODS

Putirnfs.
A cohort of I6 1 patients with multiple myeloma were studied for a period of 14 months after informed consent and with ethical approval from the University of Alberta Human Ethics Committee. Clinical and experimental information was maintained in a set of linked databases using DbaseIII+ (Borland, Scotts Valley, CA). The patients included 16 untreated (at diagnosis), 37 on melphelan/prednisone, 20 on Vincristine/adriamycin/dexamethasone (VAD) 12 on biologic response modifiers interferon ( I F N ) or IFN plus interleukin-2 (IL-2), and 60 off chemotherapy. For some patients analyzed for prolonged periods of time, a single patient may appear in several of these groups. Patients on intermittent chemotherapy were studied at least 4 weeks after their latest treatment. The definition of clinical stages was as described by Durie and Salmon.' Among these patients, treatment groups included melphalan/prednisone, vincristine/Adriamycin/high-or low-dose dexamethasone, or biologic agents such as IFN-a or IFN/IL-2. Patients were designated as off treatment 2 months after their last cycle ofchemotherapy. However, most patients in this category had been off treatment for longer periods of time.
P~~ri~cu~ionc~fperipherulhloodrnonon~rcleurcells(PBMCs). Venous blood samples were drawn into heparinized vacutainer tubes, and the PBMCs were isolated on a Ficoll-Paque (Pharmacia, DorVal, Quebec. Canada) density gradient. Cells harvested from the interface were washed twice in RPM1 (GIBCO, Grand Island, NY) and resuspended in phosphate-buffered saline (PBS), containing 2% fetal calf serum (FCS) (HyClone Labs Logan, UT). Methods for depletion of adherent cells were carefully avoided, because the presumptively malignant B cells in the blood of myeloma patients have adherent properties and are depleted by such procedure^.^ Anrihodirs. Leu-3PE (CD4), Leu-2PE (CD8), Leu-M3PE (CD14). Leu-l 5PE (CD1 lb). and Leu-l 7PE (CD38) were purchased from Becton Dickinson (Ontario, Canada). From Coulter (Hialeah, FL), we purchased B I RDI (CD20). Monoclonal antibody (MoAb) FMC63 (CD19) was IgG2a from H. Zola(Flinders Medical Centre, South Australia).30 lgG2a and IgGl fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-conjugated isotype controls were purchased from Southern Biotech (Birmingham, AL). For detection of circulating CD 19' B cells in blood of myeloma patients, either FMC63 or B4 (Coulter) gave comparable results, but these cells were not reliably detected with Leu-l2 (Becton Dickinson). The IgG2a MoAb MRK-16 detecting a surface epitope of P-gp3' was a gift from Dr T. Tsuruo (Tokyo University, J a~a n ) .~"~) CD19' cells were also evaluated for their physical properties as measured by forward (FALS) and side-angle scatter (SSc). Cells designated as small were those with SSc and FALS less than channel 400, whereas those designated as large had SSc and FALS greater than channel 400 on a linear ~c a l e .~.~ Dve-e~llxclncc!l?Fis. This procedure measures the ability ofcells to minimize retention of the mitochondrial-binding dye, rhodamine 123 (RH123). and determines whether or not the dye efflux observed, if any. is blocked by agents known to block the P-gp transport pump. A published procedure was used.34 Briefly, PBMCs from myeloma patients were loaded with RH123 (150 ng/mL) (Sigma, St Louis, MO), followed by washing and resuspension in medium with or without the blocking agent for 3 hours at 37°C to allow dye efflux. Blocking agents were either verapami13' at 50 mmol/L, or CsA29.36 (Sandoz Pharmaceuticals, Dorval Quebec) at I & n L unless otherwise indicated. Cells were then stained with a direct PE conjugate ofthe indicated MoAbs, with the blocking agent included in all buffers for the samples treated with it, washed, resuspended in PBC with or without the blocking agent, and run immediately on the FACScan. The RH 123 emission was collected in the FLI channel and emissions from MoAbs defining surface phenotype in the FL2 channel. FACScan compensation was set to reduce as much as possible the RH123 emissions detected in FL2. For staining of B cells using dyes emitting in FL2. we used a cocktail of CD19-PE + CD2O-RDI to optimize detection of B cells based on their coexpression of these two B-cell markers. This was necessary because detection of myeloma PBMC B cells using PE conjugates of CD I9 was suboptimal and variable between patients, unlike the highly reliable staining with FITC conjugates. This was true for both FMC63-PE and B4-RDI (Coulter). Controls for each sample established that the total number of B cells detected with the cocktail at the end of the functional dye-efflux assay was comparable with that before the pumping procedure. as measured with either CD19-FITC or the CD 19-PE + CD2O-RD I cocktail.
There were several important aspects to this procedure. It was essential that the cells be used on the same day the blood was collected. The dye efflux was compromised even if stored blood or purified cells were warmed before the assay. For those samples with blocking agent. the agent was included in all buffers and washes for all steps of the procedure to maintain inhibition of the P-gp pump. The quality of the data was much improved by the inclusion of FCS in all buffers. The RH 123 dye efflux by myeloma PBMCs was equivalent to that of highly drug-resistant cell lines used as controls, and like the cell lines, was efficiently blocked by CsA (0.5 to 2.0 rg/ mL) or verapamil(50 pmol/L).
On FACScan analysis, staining for surface phenotype indicated reduced density of MoAb binding after dye-efflux procedures and shrinkage ofthe large subset of B-lineage cells. This was exclusive to the monoclonal large B cells in myeloma as T cells or monocytes in myeloma samples retained their normal staining and size profiles, and normal B cells were also unaffected, indicating the procedure itself was not responsible. This may reflect the volume-regulated chloride channel activity associated with P -~P , "~ and appears to selectively affect surface phenotype and size of the large B cells, reducing them to the size of small B cells, and leaving monocytes in the samples, as defined by Leu-M3 staining in a separate aliquot, as the only large cells. The total number of B cells remained constant indicating no cell loss. To control for these effects, aliquots of the permeabilized cells or their progeny with 4"6'-diamidino-2-phenylindole (DAPI), a dye that binds in the AT-rich minor groove of Quantitation of DNA using DAPI does not appear to be affected by the stages of the cell cycle." Myeloma PBMCs at the indicated day of culture were harvested and stained with FMC63 FITC (CD19), Leu-3PE (CD4). and DAPI. Surface phenotyping utilized the logrithmic scale of fluorescence intensity and DAPI staining utilized the linear scale. Cells were resuspended in 1 mL of 50% FCS/PBS. followed by permeabilization with 3 mL of 70% ethanol at 4'C. RNAse treatment. and staining with DAPI (1.5 fig/ mL final c~ncentration).'~-~' Samples were run immediately after staining on the ELITE (Coulter) flow cytometer with FITC and PE excited by the argon laser (488 nm), and DAPI excited at 353 nm by the water-cooled laser. As an internal standard. and to define the placement ofthe diploid peak, all samples included the addition of chicken red blood cells (CRBCs). Diploid human cells bind approximately three times as much DAPI as do CRBCS.~' but in our hands this varied somewhat for CRBCs from individual chickens from 3.05 to 3.54, although with any given preparation of CRBCs. this value remained constant. The value to be applied for the definition of diploid was determined by staining unfractionated uncultured human thymocytes, which have a very distinct large diploid peak with a narrow coefficient of variation (CV) (2.9 to 4.0). The use of the CRBC internal standard was essential for evaluating the broad distributions of DAPI staining obtained when the cultures included cells that had become apoptotic. The narrow CVs of DAPI staining allowed good resolution of hypodiploid staining, and the emission spectrum did not overlap the dyes used for surface phenotyping. Isotype-matched control staining were always performed to evaluate the staining with test antibodies. Files of 10 to 30.000 cells were analyzed from listmode using the ELITE software. Electronic gates were set for B cells (CD19') or T cells (CD4+), and the DAPI profile was plotted as a histogram. The number of apoptotic cells was defined as those cells with a DNA content less than diploid, both with a severely reduced DNA content or with hypodiploid amounts of DNA seen as a lower-intensity shoulder on the diploid peak. This method has been used to quantitate apoptosis among human and murine thymocyte^.^*-^^ The reduced DNA content detectable with DAPI is most likely caused by a reduced ability of the dye to bind to condensed DNA and, perhaps. to degraded fragment^.^' (Table I) . Patients were grouped according to their treatment status and type. Previous work with this same cohort of patients has shown 26% to 36% CD19' B cells among PBMCs or 0.2 to 0.6 X IOy CD1 9' cells/L blood, and confirmed monoclonality.'.7.9.'2,13 The presence of monoclonal B cells in blood varies over the course of the disease with maximal numbers during progressive phases of the disease and in relapse.'" Based on physical properties of forward and side scatter, PBMC B cells were divided into a small and a large subset. The small subset shares some properties with normal resting B cells but small B cells in myeloma PBMCs are phenotypically distinct in their expression of CDIO, PCA-I and CD45R0.6.7.9 The large subset consists of late stage B cells expressing CD1 1 b. CDIO, PCA-1 and CD45R0.6.7.9 Based on two-color IFanalysis as illustrated in Fig I , Table l shows that in all patients. irrespective of treatment, 42% to 75% of patients had expression of P-gp on 6% to 57% of the small B cells(co1umns I and 2). A major proportion ofpatients, 79% to 91%. had 75% to 84% of large B cells expressing P-gp. In all treatment categories, a small proportion of patients had no or very few B cells expressing detectable P-gp.
In myeloma, the multidrug resistance transport pump, Pgp, is expressed at moderate to high density on blood B cells before any chemotherapy, and the overall proportion of such B cells does not increase either in number or in density during chemotherapy.
Exprcwion (?/'P-gp on ln~rlomu BM B-lineage ctdls is incrtuwl posttrcatr?lc'nt ./Or patimts Mith progrtwivc or rc>-
Iupsed di.scu.sr. The expression of P-gp on plasma cells in bone marrow (BM) of myeloma patients is controver- Table 2 reports the expression of surface P-gp on CD 19' B-lineage cells in BM cells taken during various phases of disease. In myeloma patients, phenotypic analysis detects abnormal numbers of CD19' cells not always detectable by morphologic analysis as plasma cells. Myeloma BM cells were subdivided into small and large subsets. The mean number of CD 19' cells in either subset was comparable for all the groups listed in Table 2 , although there w d S considerable variation within each group. Untreated patients had low or no expression of P-gp on BM B/plasma cells, in contrast to the abundant expression on PBMC B cells from these same patients. Fifty-four percent of untreated patients had little or no detectable P-gp expression in BM cells (Table 2 , line 1 13). Analysisoftreated patients categorized according to phase of disease, as compared with untreated patients, showed a significant increase in P-gp expression on CD I9+ small BM cells in progression and relapse (Table 2 , lines 3 and 4). For all treated groups, the number of P-gp+ large CD19' BM cells was higher than in untreated patients. Nearly all patients, had greater than 20% P-gp+ CD I9+ BM cells ( 
Values are the mean f SE of the indicated number of samples. None of the groups had a value significantly different from the untreated group. PBMC samples were stained with CD1 9-FITC and MRK-16/goat-antimouse-lg PE. Files of 10 to 20,000 cells were gated for small or large CD1 9' B cells as indicated in Materials and Methods and the expression of P-gp plotted as a histogram. Positive staining with MRK-16 (P-gp) was compared with that of identically gated samples stained with an lgG2a isotype control. Intensity of staining ranged from 80 to 600 channels brighter than the isotypecontrol staining with the majority of samples giving an intensity in the range of 200 to 400 channels above the background on a logarithmic scale of 1024 channels. For most patients, 70% to 95% of the total staining with MRK-16 was accounted for by the CD1 9' population. All patient groups had mean values of B cells from 26% to 36% of PBMCs, approximately X of which were small B cells'
Because in all groups, a proportion of patients For untreated patients and those in the progressive phase of the disease, approximately 4070 of small CD1 9' PBMCs are P-gp+. and only a few samples are P-gp- (Fig 2, top) . Patients in temporary remissim have an increased proportion of P-gp+ small B cells. Patients responding to that therapy, had a significant reduction in the proportion of P-gp+ small B cells and a large number of patients lacked detect- Values are the mean -c SE. Staining was as described for Table 1 , and the staining intensity for all treated groups was comparable with that of PBMC B cells. The staining with MRK-16 for BM cells from untreated patients was often quite low. Comparison of clinical evaluation and flow cytometric studies indicated that the majority of the B-lineage cells, including mature plasma cells, expressed a low but detectable density of CD1 9. B-lineage cells were subdivided into small and large subsets, but the relationship of small CD19' BM cells to those in PBMCs is unclear. They have a phenotypic profile suggesting a very late-stage B or preplasma ce11.6,9
Abbreviations: Tr/Off. treated and Off treatment; Asympt, asymptomatic at the time the samples was taken; Prog, progressive disease at the time the sample was taken; "Remis," temporary remission.
P S .01 compared with untreated BM. P-gp expression on large PBMC B cells was considerably increased in all treatment groups as compared with untreated patients, with the highest proportions, 8O%# to 90% of CD 19' B cells expressing P-gp, among patients with progressing disease and those in temporary "remission" (Fig 2.  bottom) .
Patients were evaluated for P-gp expression on PBMCs and BM B-lineage cells at multiple time points over a 14 month period. Figure 3 shows the dynamic nature of P-gp expression on B lineage subsets. For patient 1 (Fig 3, A) expression of P-gp on BM cells was on only a small subset and at low surface density, whereas on PBMCs, a substantial proportion of small and large B cells expressed P-gp at high surface density. The proportion of P-gp+ PBMC B cells increased with the initiation of VAD therapy and at the end of the VAD cycle, P-gp was expressed on nearly all blood and BM B-lineage cells. although this patient was in temporary remission. In late 1992. the patient received an autologous transplant. The 10/92 time point shows the high P-gp expression on PBMC B cells at the time of transplant, and on the BM cells transplanted. The expression of P-gp has decreased slightly posttransplant. Patient 2 (Fig 3 , B) had Pgp+ cells in both blood and BM at the time of diagnosis. During treatment with melphalan/prednisone. expression of P-gp varied in an apparently cyclical manner among small PBMC B cells and in a less dramatic way for the large PBMC B cells. In a sample taken during temporary rcmission, BM cells had strong expression of P-gp.
These individual profiles illustrate the dynamic patterns of P-gp expression seen among the 16 1 patients analyzed, in whom the blood appears to be a persistent but variable reservoir of multidrug resistant B-lineage malignant cells.
P-gp' blood B d l . \ incldo U sub.sc>t of DNA h?pudipIoid
Lcl1.s. To confirm their presumptive malignant character, myeloma B cells expressing P-gp were analyzed for their DNA content. BM plasma cells exhibit extensive DNA ane~ploidy,~"~' and recent work indicates that nearly all patients have circulating hyperdiploid B cells with restricted light-chain expression." Myeloma PBMCs from a patient in relapse, on treatment or untreated at diagnosis were stained for surface phenotype and DNA content (Fig 4, A  through C) , and the DNA content of P-gp' B cells evaluated. Files were gated for small non-B cells and the position ofthe DNA peak compared with that of T cells in a replicate aliquot of PBMCs to establish the position of the diploid peak. B cells were considered to be hyperdiploid only iftheir DNA content exceeded that of T cells. Figure 3 shows that both small and large CD 19' P-gp' B cells had a substantial DNA hyperdiploid subset with 5% to IO% excess DNA (Fig 4, top and middle panels). Hyperdiploid cells were less frequent among the P-gp-B cells (Fig 4, bottom panels) .
PBMC ' B ccll.v dye in individual cells. The involvement of P-gp in the dye efflux was confirmed by the demonstration that dye efflux was blocked by verapamil or CsA. To define subsets of PBMCs, cells were loaded with RH 123, allowed to efflux dye in the presence or absence of CsA and then stained for surface CD19 or CD1 I b (Fig 5) . The representative histograms for two patients are shown. For both patients, the majority of CD 19+ cells were able to efflux dye, and this efflux was blocked by CsA. Gating for the CD1 1 b' PBMCs, which defines the CD 19' large B cells,' showed efficient CsA-sensitive efflux in this subset.
The functional activity of P-gp was also assessed among the presumptively nonmalignant components of the PBMCs in myeloma patients. A representative experiment is shown in Fig 6. For this patient, CD4+ and CD8+ T cells included 39% to 42% of cells expressing functional P-gp.
However, monocytes, defined by their expression of CD14, retained dye even in the absence of CsA, indicating a lack of P-gp or other transport mechanism on monocytes and confirming observations on monocytes from normal don o r~.~~ The inability of monocytes within myeloma PBMCs to efflux dye contrasts strongly with the active dye efflux of the B cells represented by the CD1 Ib+ PBMCs. This provides further evidence that the monoclonal CD 19+ CD l l b+ PBMCs described here and elsewhere6v9 are distinct from monocytes. Table 3 summarizes the dye-efflux patterns in PBMC subsets for 32 patients, and the inhibitory effects of CsA or verapamil on this efflux. In all patients, the CD 19' B-cell subset and the CD 1 I b+ cells exhibited CsA-or verapamil-sensitive dye efflux for 58% to 63% of the gated cells (Table 3 , lines I and 2). For some of patients, a subset of the gated population had CsA-or verapamil-insensitive dye efflux. Among T cells, all dye efflux was CsA-sensitive. CD4+ cells had approximately half as many cells capable of effluxing dye as did the CD8+ cells, consistent with the properties of T cells from normal donors.54 Monocytes from myeloma patients had little or no detectable dye efflux either without or with CsA (Table 3, line 5 ). This work confirms that the CD19+ CD1 1 b+ B cells in myeloma PBMCs are distinct from monocytes in the same PBMC sample.
BM B-lineage cells in myeloma have a reduced ability to eflux dye. Figure 7 shows the dye-efflux patterns of B-lineage cells from blood and BM samples taken from a myeloma patient immediately before autologous BM transplantation. CD 19' and CD1 1 b+ B cells in PBMCs showed active dye efflux that was blocked by CsA. Among myeloma BM cells, the CD 19+ cells had reduced dye efflux with only 40% effluxing dye in the absence of CsA. Gating to include only the CD3gh' BM plasma cells yielded a population that lacked a functional transport pump and retained dye even in the absence of CsA. This figure confirms with a functional assay the conclusion that the predominant reservoir of drugresistant disease resides among the blood B-cell population and on the less differentiated B cells of BMCs. A similar pattern was seen for three different myeloma BM samples.
P-gp protects B cells in myeloma
PBMCs from the cytotoxic effecfs of adriamycin. Although it is a reasonable conclusion that dye efflux reflects resistance to drug-induced cell death, this assumption was tested by culture of myeloma PBMCs with various doses of adriamycin in the presence or absence of CsA (Fig 8) . The steady-state concentration of adriamycin in the blood of treated patients is in the range of 0.01 pg/mL,** and is known to be effluxed by P-gp.35, 55 The effects of Adriamycin on the B and T cells present in myeloma PBMCs were determined by a multiparameter IF study of surface phenotype and DNA content as a measure of apoptotic cell death (Fig 8) . The same aliquot of cells was stained for both CD 19 and for CD4, files were gated for both patient in relapse, the middle is from a patient on intermittent che-
motherapy, and the bottom from an untreated patient at diagnosis.
For CRBCs were always added as an internal standard to determine the position of the diploid peak. Apoptotic cells were defined as those cells with a DNA content less than 95% of the diploid amount. A reduced DNA content reflects DNA fragmentation and condensation?246 Treatment of myeloma PBMCs for 3 days with 0.01 pg/ mL Adriamycin, the steady-state level achieved in vivoz8 with or without CsA gave only minimal reductions in DNA content of either B or T cells (Fig 8, left row) . Myeloma
PBMCs cultured with 0.1 pg/mL Adriamycin, IO-fold higher than the in vivo level achieved during therapy, resulted in a reduced DNA content for only 19% of B cells and 5% of T cells. However, culture with Adriamycin plus CsA resulted in extensive DNA degradation by 6 1 % of the B cells with few remaining diploid B cells, whereas the majority of T cells (76%) remained diploid with reduced DNA content among only 23%. Thus, these conditions appear to be somewhat selective for the malignant CD19' B-cell population while sparing the CD4' T cells (Fig 8, middle row) . Treatment of PBMCs with CsA alone gave a DNA staining pattern identical to that of untreated PBMCs after 3 days of culture.
The extensive damage to B cells at 0.1 pg/m of Adriamycin required inhibition of the transport pump of the P-gp pump by CsA. However, the pumping mechanism could be overwhelmed by a IO-fold increase in the concentration of Adriamycin to 1.0 pg/mL (Fig 8, right row) . At this high 
CDllb+ Myeloma PBMC
dose (100 times the in vivo levels), the pump appeared ineffective as 98% of the B cells were apoptotic and the majority of T cells were also affected. Only 2% of B cells and 44% of T cells remained diploid. Coculture with both Adriamycin and CsA further reduced the remaining diploid T cells to only 24%. Thus, the presence of the multidrug transport pump on PBMC B cells from myeloma patients renders them resistant to all but extremely high doses of cytotoxic drug. Inhibition of the pump by CsA allows a relatively selective B-cell kill by a lower dose of Adriamycin that spares most T cells.
DISCUSSION
This study shows the expression of the multidrug transport pump, P-gp, on B-lineage cells of blood and BM from patients with multiple myeloma. In untreated patients, expression of P-gp is predominant among the monoclonal blood B cells, but is weakly expressed among CD 19+ B-lineage cells in the BM, with no detectable expression on end-stage plasma cells. After treatment, the proportion of Blineage cells expressing P-gp increases in both blood and BM. The proportion of P-gpf B cells in blood vaned throughout the course of disease suggesting that expression of P-gp did not reflect a heritable genetic change resulting in overexpression, but was rather a part of normal B-lineage differentiation. P-gp is found on normal stem cells,34 other BM ~e l l s~~-~' and normal T cells,533s4 but is absent on monoc y t e~.~~.~~ Normal B cells express P-gp and mediate CsA-sen- Values are the mean t SE. The subsets noted above derive from the same set of patients. The inhibitor used was CsA (1 pg/mL) for 20 patients and verapamil(50 pmol/L) for 12 patients. All patients assayed for dye efflux by CD4, CD8, or CD14 subsets were also assayed for CD1 9
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and CD1 1 b sets. Patients with CsA-insensitive dye efflux included those patients for whom greater than 20% of the indicated subset effluxed dye in the presence of CsA. For the most part, the patients indicated t o have CsA-independent efflux, for eg, CD14, also had CsA-insensitive efflux for CD1 1 b and CD19' subsets. However, one patient had completely CsA-insensrtrve CD1 4+ dye efflux but completely CsA-sensitive CD 1 1 b' efflux. Abbreviatlon: V, verapamil. * P S ,0001 compared with CD19'cells. t P S ,0001 compared with CD8+ cells.
sitive dye e f f l~x . '~.~' Among BM B-lineage cells, increased expression of P-gp was apparent after chemotherapy, but the proportion of P-gp+ CDI9+ cells was equivalent for relapsed patients and those in temporary remission. For a substantial number of myeloma patients, a large proportion of monoclonal P-gp' B cells were resident in cell populations used for autologous BM transplants. The malignant character of these circulating B cells was confirmed by their extensive abnormality of DNA content characteristic of malignant cells but absent from normal B cells. P-gp' B cells included both diploid and hyperdiploid B-cell subsets, but P-gp-B cells were predominantly diploid. This suggests that the majority of abnormal DNA replication occurs among the multidrug resistant B cells. P-gp has homology to the MHC Class I peptide transport pump,59 transports peptides,60,6t has an associated volumeregulated chloride channel,37 and appears as part of the normal differentiation of human blood or splenic B cell^.^^^^' Pgp is expressed as part of a developmental pattern during the mature B-cell stage, and appears to be lost as B cells differentiate to end stage plasma ~e l l s . '~~~* It is plausible that circulating monoclonal B cells in myeloma, which represent the least differentiated members of the malignant constitute a reservoir of drug resistant disease that is continuously replenished as differentiation proceeds.
The work reported here supports this view. End-stage plasma cells lacking CD 19 and CD45 have presumably lost the capacity to respond to activating signals from the outside environment and are unlikely to require a peptide transport pump. In myeloma patients, seven of seven completely lacked expression of P-gp on CDi9-plasma cells. CD38h' plasma cells were unable to efflux dye, confirming the absence of a functional drug pump. Other work shows that BM samples from untreated myeloma patients have weak expression of MDR1 mRNA26s27 or lack surface P-gp. 62 In 
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CD38hi BM contrast, circulating B cells expressed a high density of P-gp, and effectively mediated CsA-sensitive dye efflux. CD 19' B cells in the BM have a relatively infrequent expression of Pgp and a limited ability to efflux dye as compared with PBMC B cells. In over half of the untreated patients, P-gp is absent or only weakly expressed among BM cells, but is strongly expressed on PBMC B cells. Because these patients have not yet been exposed to chemotherapy that might select for drug-resistant populations, the distribution of P-gp is likely to reflect developmental patterns within the malignant clone. The findings here ofa high proportion of P-gp surface staining on a high proportion of CD 19' BM cells from patients subjected to chemotherapy appears to contrast with an extensive study analyzing cytoplasmic P-gp expression on plasma cells.62 This conflict is likely to be more apparent than real, because the cells staining with CD I9 as detected by flow cytometry may include a high proportion of cells not scored as plasma cells by Grogan et Our finding that CD19-plasma cells from untreated patients lacked detectable P-gp expression confirms their work.
With the initiation ofchemotherapy, the proportion of Pgp expressing cells within the malignant lineage increases in all compartments suggesting continuous kill of sensitive components and consequent selection of drug-resistant subsets. Even though these subsets are likely to differentiate, lose P-gp, and become sensitive themselves, they are probably continuously replenished by the generative compartment of myeloma. We predict that as the malignant clone differentiates in myeloma, P-gp+ subsets are continuously generated and upon introduction of chemotherapy, are enriched through selective kill of P-gp-differentiation stages. The introduction of altered developmental patterns by chemotherapy-induced kill may influence the course ofdisease more profoundly than would selective pressure on P-gp+ Bcell stages. The perturbation ofclonal growth by chemotherapy may be responsible for effusive production of monoclonal B cells in the blood, perhaps accounting for the increased numbers of blood B cells postchemotherapy in many patients.'.'' The role of P-gp expression in myeloma remains to be established. Other mechanisms of drug resistance may play a r~l e .~~,~' Melphalan, the most commonly used therapeutic agent, is a substrate for the P-gp transporter in some cells, 18.63-67 as are vincristine or Adriamycin,16 and recent evidence indicates that steroids such as dexamethasone and cortisol are transported by P-gp.'6,68,69 The efficacy of aggressive VAD regimens is seriously compromised by the presence of B-lineage malignant cells with functional P-gp from myeloma patients to Adriamycin was confirmed in vitro. Doses of Adriamycin to which the PBMC B cells are almost completely resistant become highly cytotoxic in the presence of CsA. Furthermore, this effect is partially selective to the malignant B cells while sparing the majority of the presumptively normal T cells in the cultures.
The presence of CsA renders an ineffective dose of Adriamycin nearly as effective as a IO-fold-higher dose that presumably overwhelms the transporter mechanism. However, it is important to note that at doses of adriamycin achieved in vivo, no cytotoxic effect was detectable even in the presaCtivity.14.19.20.23 The resistance of monoclonal blood B cells ence of CsA. A dose IO-fold higher than those currently achievedz8 appears to be necessary to mediate the substantial kill observed here. Such a dose was effective on, and at least partially selective for, malignant B cells, but only in the presence of CsA. Our results suggest that in the absence of CsA, an in vivo dose 100-fold higher than currently attained is needed for killing of circulating B cells in myeloma. However, in addition to known toxic effects of Adriamycin, such a high concentration would almost certainly compromise normal hematopoietic and lymphoid development.
Although P-gp is not likely to be the only determinant of Adriamycin toxicity, this work suggests the need for a cautious but perhaps, more aggressive approach to combining high-dose chemotherapy with P-gp inhibitors such as CsA. T cells, any remaining normal B cells'3 and presumably any hematopoietic stem cells34 are likely to be spared by conventional chemotherapy through their active drugFor personal use only. on October 22, 2017. by guest www.bloodjournal.org From efflux mechanisms. Our work indicates that a putative generative compartment of the myeloma malignant clone present in the blood, the monoclonal CD19+ B cells, is also spared.
